There are currently 537 clinical trials in Gainesville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Florida /ID# 144834, University of Florida Health Science Center - Gainesville, University of Florida Shands Cancer Center and University of Florida College of Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Immune Function and the Progression to T1D
NCT05899439
Recruiting
To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
03/04/2025
Locations: Kieran McGrail, Gainesville, Florida
Conditions: Type 1 Diabetes
Register for Updates
Clinical Trial to Compare Clear Aligners' Auxiliaries on Rotational Accuracy
NCT06418984
Recruiting
This randomized clinical trial aims to assess the effectiveness of optimized attachments, IPR and a combination of the two techniques on the rotational accuracy of canines with clear aligners
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/04/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Rotation of Tooth
Register for Updates
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
NCT06488222
Recruiting
Bladder cancer is the 8th most common cancer in the UF Health Cancer Center catchment area and the 7th most common cancer presenting to UFHealth. Most newly diagnosed cases are stage I bladder cancer, which is defined by having no deep muscle invasion and no evidence of disease beyond the bladder. The current use in BCG (Bacillus Calmette-Guerin) refractory disease and the ongoing evaluation in BCG naïve high-risk disease support evaluation of intravesical gemcitabine and docetaxel in decreasing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Bladder Cancer
Register for Updates
Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging
NCT05457725
Recruiting
Much of human interaction is based on trust. Aging has been associated with deficits in trust-related decision making, likely further exacerbated in age-associated neurodegenerative disease (Alzheimer's disease/AD), possibly underlying the dramatically growing public health problem of elder fraud. Optimal trust-related decision making and avoiding exploitation require the ability to learn about the trustworthiness of social partners across multiple interactions, but the role that learning plays... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/03/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Aging, Cognitive Change, Neurocognitive Disorders, Mild
Register for Updates
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
NCT06352359
Recruiting
This is a Phase I open label, dose-escalation study of intravenous (IV) infusion of ONC-841 as a single agent in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841 starting from 0.03 mg/kg to 30 mg/kg.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: UF Health Cancer Center, University of Florida, Gainesville, Florida
Conditions: Advanced Solid Tumor
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: UF-Health Cancer Center Gainesville, Gainesville, Florida
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
NCT05836571
Recruiting
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Conditions: Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Soft Tissue Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Register for Updates
Exactech Shoulder Post Market Clinical Follow-up Study
NCT05603728
Recruiting
The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
02/26/2025
Locations: UF Health Orthopaedics and Sports Medicine Institute, Gainesville, Florida
Conditions: Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections
Register for Updates
Study of ATX-01 in Participants with DM1
NCT06300307
Recruiting
The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo. There will be a single-ascending dose part of the trial and a multiple-ascending dose part. In the single-ascending dose, participants will receive one dose of ATX-01 or placebo. In the multiple-ascending dose part, participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
02/26/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Myotonic Dystrophy 1
Register for Updates
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
NCT02368041
Recruiting
This is a single-center, non-randomized study.The study staff will use the InSpectraTM tissue oxygen saturation (StO2) monitor manufactured by Hutchinson Technology to measure baseline StO2 levels after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained, a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero (whi... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/25/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Heart Failure
Register for Updates
Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
NCT05732779
Recruiting
We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.
Gender:
ALL
Ages:
Between 10 years and 21 years
Trial Updated:
02/25/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Heart Transplant Rejection, Immune Suppression, Pediatric Heart Transplant, Medication Nonadherence, Health Behavior, Remote Monitoring, Patient Engagement
Register for Updates
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
NCT05874921
Recruiting
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Register for Updates